ID   JVE222
AC   CVCL_EG26
SY   JVE-222
DR   cancercelllines; CVCL_EG26
DR   DSMZ; ACC-821
DR   DSMZCellDive; ACC-821
DR   GEO; GSM1655608
DR   GEO; GSM1655630
DR   Wikidata; Q54899182
RX   PubMed=26894854;
RX   PubMed=28931069;
CC   Doubling time: ~70 hours (DSMZ=ACC-821).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=26894854).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=26894854).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Colon, ascending; UBERON=UBERON_0001156.
ST   Source(s): DSMZ=ACC-821; PubMed=26894854
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,12 (PubMed=26894854)
ST   D13S317: 12 (DSMZ=ACC-821)
ST   D16S539: 9,12
ST   D18S51: 12,14
ST   D19S433: 14,15
ST   D21S11: 29,32 (DSMZ=ACC-821)
ST   D21S11: 29,32.2 (PubMed=26894854)
ST   D2S1338: 17,23
ST   D3S1358: 16,18
ST   D5S818: 9,11
ST   D7S820: 10,11
ST   D8S1179: 13,15
ST   FGA: 24
ST   Penta D: 11
ST   Penta E: 5,11
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 16
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 10-04-25; Version: 16
//
RX   PubMed=26894854; DOI=10.18632/oncotarget.7391; PMCID=PMC4924731;
RA   Boot A., van Eendenburg J.D.H., Crobach S., Ruano D., Speetjens F.,
RA   Calame J., Oosting J., Morreau H., van Wezel T.;
RT   "Characterization of novel low passage primary and metastatic
RT   colorectal cancer cell lines.";
RL   Oncotarget 7:14499-14509(2016).
//
RX   PubMed=28931069; DOI=10.1371/journal.pone.0184900; PMCID=PMC5607170;
RA   Boot A., Oosting J., van Eendenburg J.D.H., Kuppen P.J.K., Morreau H.,
RA   van Wezel T.;
RT   "Methylation associated transcriptional repression of ELOVL5 in novel
RT   colorectal cancer cell lines.";
RL   PLoS ONE 12:e0184900.1-e0184900.16(2017).
//